T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants

BACKGROUND: Tumor-infiltrating lymphocytes (TILs) represent a prognostic factor for survival in primary breast cancers (BC). Nonetheless, neoepitope load and TILs cytolytic activity are modest in BC, compromising the efficacy of immune-activating antibodies, which do not yet compete against immunoge...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Messaoudene, M., Mourikis, T.P., Michels, J., Fu, Y., Bonvalet, M., Lacroix-Trikki, M., Routy, B., Fluckiger, A., Rusakiewicz, S., Roberti, M.P., Cotteret, S., Flament, C., Poirier-Colame, V., Jacquelot, N., Ghiringhelli, F., Caignard, A., Eggermont, A.M.M., Kroemer, G., Marabelle, A., Arnedos, M., Vicier, C., Dogan, S., Jaulin, F., Sammut, S-J., Cope, W., Caldas, C., Delaloge, S., McGranahan, N., André, F., Zitvogel, L.
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614969/
https://ncbi.nlm.nih.gov/pubmed/30924846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz112
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki